Asset Evaluation

Home / Asset Evaluation

Asset Evaluation

Probability of commercial success is different from probability of clinical success.

Atebion BDS believes that early commercial insight to a disease target product profile (DTPP) or a candidate’s target profile (TPP) is a prerequisite for success, whether this relates to completing an in- or out-license or a successful product launch.

High quality techno-commercial evaluations represent a core component of all our services.

Evaluations from Atebion BDS provide the following components;

Disease area overview

  • Clinical need and its evolution
  • Leading drugs and profiles
  • Key success factors and barriers to success
  • Regional needs and differences

Pipeline assessment and competitive landscape

Sales and forecasts

  • WW. by Region and/or key market

S&M approaches and costs

Market overview

  • Current and evolving

Impact of new entries and genericisation

Emerging markets vs established

Atebion BDS can offer early insight market research to support commercial evaluations. Probability of commercial success is different from probability of clinical success.

Testimonials

What Our Clients Say